慢性肾功能不全对药动学影响研究进展

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (6): 715-720.

• 综述与讲座 • 上一篇

慢性肾功能不全对药动学影响研究进展

黄原原^1,2, 张浩¹, 易斌¹, 付志敏¹, 阳国平^1,2

¹中南大学湘雅三医院,长沙 410013,湖南;
²中南大学药学院,长沙 410013,湖南

收稿日期:2012-03-20 修回日期:2012-05-24 出版日期:2012-06-26 发布日期:2012-06-25
通讯作者: 阳国平,男,教授,研究方向:药代动力学、临床药理学。Tel: 0731-88618338 E-mail: ygp9880@163.com
作者简介:黄原原,女,硕士研究生,研究方向:临床药理学。Tel: 15116307340 E-mail: yuanhyy1986@163.com

Advances of the influence of chronic renal failure on the pharmacokinetics

HUANG Yuan-yuan^1,2, ZHANG Hao¹, YI bing¹, FU Zhi-min^1,2,, YANG Guo-ping^1,2

¹The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China;
²The Pharmacy College of Central South University, Changsha 410013, Hunan, China

Received:2012-03-20 Revised:2012-05-24 Online:2012-06-26 Published:2012-06-25

摘要/Abstract

摘要： 慢性肾功能不全是临床常见疾病之一,主要经肾消除及主要经非肾途径消除的药物,药代动力学及药效学均受慢性肾功能不全疾病的影响。肾功能不全尤其是终末期肾病不仅直接减少药物的排泄,还能影响药物吸收、药物转运及药物代谢,从而影响药物的非肾消除。肾功能不全可直接抑制药物代谢酶及转运体的活性并减少酶及转运体在胃肠道、肝脏等多个器官的mRNA及蛋白的表达。引起这种抑制作用的原因尚不明确,血液透析可以部分抵消或逆转这种抑制作用并存在透析消除。

关键词: 肾功能不全, 药动学, 研究进展

Abstract: The chronic renal failure(CRF) is one of the common diseases in clinic. CRF affects the pharmacokinetics and pharmacodynamics of drug which either eliminate by renal or by nonrenal routes. The tests in vivo and in vitro demonstrated that renal impairment especially end-stage renal disease (ESRD) not only decreased the excretion by kidney, but also the alterations in the activities of and interplay between uptake and efflux transporters and metabolic enzymes significantly affected the PK disposition and resulting exposure of drugs cleared through nonrenal. CRF can directly inhibit the activity of various metabolic enzymes and transporters and in the other sides the CRF can down-regulate the mRNA and protein expression of metabolic enzymes and multiple intestinal and hepatic drug transporters. The reasons of those inhibition effects need more researches. The hemodialysis can partially offset or reverse this kinds of inhibition and dialysis clearance exist in the patient with ESRD.

Key words: Chronic renal failure, Pharmacokinetics, Advances

中图分类号:

R969

黄原原, 张浩, 易斌, 付志敏, 阳国平. 慢性肾功能不全对药动学影响研究进展[J]. 中国临床药理学与治疗学, 2012, 17(6): 715-720.

HUANG Yuan-yuan, ZHANG Hao, YI bing, FU Zhi-min, YANG Guo-ping. Advances of the influence of chronic renal failure on the pharmacokinetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(6): 715-720.

参考文献

[1] Coresh J, Selvin E, Stevens LA,et al. Prevalence of chronic kidney disease in the United States[J]. JAMA, 2007,298(17):2038-2047.
[2] Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing[J]. Am J Kidney Dis,2008, 51(3):373-384.
[3] Evans RS, Lloyd JF, Stoddard GJ, et al. Risk factors for adverse drug events: a 10-year analysis[J]. Ann Pharmacother, 2005, 39(7/8):1161-1168.
[4] Manley HJ, Cannella CA, Bailie GR,et al. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis[J]. Am J Kidney Dis,2005,46(4):669-680.
[5] AW Dreisbach. The influence of Chronic Renal Failure on drug metabolism and transport[J].Clin Pharmacol Ther, 2009,86(5):553-556.
[6] Leblond FA, Giroux L, Villeneuve JP, et al. Decreased in vivo metabolism of drugs in chronic renal failure[J]. Drug Metab Dispos, 2000,28(11):1317-1320.
[7] Leblond FA, Petrucci M, Dube P, et al. Downregulation of intestinal cytochrome P450 in chronic renal failure[J]. J Am Soc Nephrol, 2002,13(6):1579-1585.
[8] Dani M, Boisvert C, Michaud J, et al.Downregulation of liver drug metabolizing enzymes in a murine model of chronic renal failure[J]. J Am J Physiol Renal Physiol, 2010,38(3):357-360.
[9] 李晓宇,刘皋林.CYP 450酶特性及其应用研究进展[J].中国临床药理学与治疗学,2008,13(8):942-946.
[10] Karara AH, Frye RF, Hayes PE, et al. Pharmacokinetics of abecarnil in patients with renal insufficiency[J]. Clin Pharmacol Ther, 1996,59(5):520-528.
[11] Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites [J]. Br J Clin Pharmacol, 2007,64(2):165-173.
[12] Dreisbach AW, Japa S, Gebrekal AB, et al. Cytochrome P4502C9 activity in end-stage renal disease[J]. Clin Pharmacol Ther, 2003,73(5):475-477.
[13] Glue P, Sulowicz W, Colucci R, et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction[J]. Br J Clin Pharmacol, 1997,44(1):91-93.
[14] Czock D, Keller F, Heringa M, et al. Raloxifene pharmacokinetics in males with normal and impaired renal function[J]. Br J Clin Pharmacol, 2005,59(4):479-482.
[15] Vormfelde SV, Muck W, Freudenthaler SM, et al. Pharmacokinetics of crivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance[J]. J Clin Pharmacol, 1999,39(2):147-154.
[16] Aronoff G, Brier M, Mayer ML, et al. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function [J]. J Clin Pharmacol, 1991,31(1):38-44.
[17] De Martin S, Orlando R, Bertoli M, et al. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis[J]. Clin Pharmacol Ther, 2006,80(6):597-606.
[18] Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure[J]. Clin Pharmacol Ther, 1993,54(6):612-620.
[19] Nolin TD, Frye RF, Le P, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam[J]. J Am Soc Nephrol, 2009,20(10):2269-2276.
[20] Simard E, Naud J, Michaud J,et al. Downregulation of hepatic acetylation of drugs in chronic renal failure[J]. J Am Soc Nephrol, 2008,19(7):1352-1359.
[21] Yu C, Ritter JK, Krieg RJ,et al.Effect of chronic renal insufficiency on hepatic and renal udp-glucuronyltransferases in rats[J]. Drug Metab Dispos,2006,34(4):621-627.
[22] Veau C, Leroy C, Banide H, et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion[J]. Nephrol Dial Transplant, 2001,16(8):1607-1614.
[23] Naud J, Michaud J, Boisvert C,et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats[J]. J Pharmacol Exp Ther, 2007,320(3):978-985.
[24] 王磊,李宁,陈西敬.转运体在药物排泄中的作用及在新药研发中的意义[J].中国临床药理学与治疗学,2009,14(4):448-454.
[25] Naud J, Michaud J, Leblond FA, et al. Effects of chronic renal failure on liver drug transporters[J]. Drug Metab Dispos, 2008,36(1):124-128.
[26] Nolin TD, Appiah K, Kendrick SA, et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity[J]. J Am Soc Nephrol,2006,17(9):2363-2367.
[27] Michaud J, Nolin TD, Naud J, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression[J]. J Pharmacol Sci, 2008,108(2):157-163.
[28] Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease[J]. Clin Pharmacol Ther, 2003,73(5):427-434.
[29] Sun H, Huang Y, Frassetto L, et al. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin[J]. Drug Metab Dispos, 2004,32(11):1239-1246.
[30] Michaud J, Naud J, Chouinard J, et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure[J]. J Am Soc Nephrol, 2006,17(11):3041-3048.

慢性肾功能不全对药动学影响研究进展

Advances of the influence of chronic renal failure on the pharmacokinetics

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[3]	黄志伟, 李熠, 徐晓勇, 张蕾, 沈一峰, 李华芳. 五种群体药动学分析工具计算结果的比较[J]. 中国临床药理学与治疗学, 2023, 28(5): 525-535.
[4]	张莉, 蔺兴遥, 尚芸, 王强. 冻伤的病理机制及治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 347-354.
[5]	燕强勇, 向大雄, 朱荣华, 杨玲凤, 阳喜定, 李晶晶, 范晓, 刘赛, 熊守军, 方平飞. 盐酸西那卡塞片在中国健康人群的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 171-177.
[6]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[7]	李晨豪, 喻喜华, 闫文浩, 柴宇霞, 李燕燕, 李锟, 李泽运. 儿童癫痫与维生素D相关性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1299-1306.
[8]	李雪静, 江金平, 李思凝, 万林飞, 周响响, 杨梿, 兰轲. 一项在中国精神分裂症受试者中评估氯氮平片的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1121-1130.
[9]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[10]	徐涛, 朱素燕, 邱相君, 徐萍. 肾功能不全患者人群中替考拉宁群体药代动力学模型的建立与验证[J]. 中国临床药理学与治疗学, 2022, 27(9): 977-983.
[11]	李苗, 俞沁玮, 江振洲, 张陆勇. LDLR的调控机制及其相关疾病与药物研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 946-954.
[12]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[13]	邓颖, 白殊同. 金圣草黄素相关药理作用机制的研究进展 [J]. 中国临床药理学与治疗学, 2022, 27(10): 1155-1162.
[14]	陈文捷, 王亚兵, 陈晓琳, 任俊玲, 赵晚君, 陈斌. 碘难治性分化型甲状腺癌的最新研究进展[J]. 中国临床药理学与治疗学, 2022, 27(1): 116-120.
[15]	贾元威, 沈杰, 储冀汝, 张翠锋, 谢海棠, 杨斌, 李相鸿, 郑丹丹, 赵静惠. 豆腐果苷及其代谢产物时辰药动学研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 986-994.